National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019

Preston Edge, Nicholas F. Scioscia, Lisa R. Yanek, Victoria L. Handa

Research output: Contribution to journalArticlepeer-review


Objective: To investigate whether the 2010 introduction of percutaneous tibial nerve stimulation and the 2013 introduction of intradetrusor onabotulinumtoxinA were associated with an increase in overall utilization of third-line treatments. Methods: Using medical claims data from IBM Marketscan database 2010-2019, diagnosis codes were used to identify adult women with overactive bladder. Procedure codes were used to identify third-line treatments. The annual proportion of patients receiving third-line treatments was calculated, as well as the proportion of each treatment received. These were modeled as a function of treatment year using linear regression; a regression coefficient significantly different from 0 was considered evidence of a significant change in utilization over time. Results: We identified 3,067,515 unique individuals with a diagnosis of overactive bladder, including 14,652 who initiated third-line treatments. The annual percentage of women with overactive bladder who initiated third-line treatment was 0.18% and did not change significantly over 10 years (P =.82). However, the proportion receiving sacral neuromodulation decreased significantly (P <.001), with a compensatory increase in intradetrusor onabotulinumtoxinA. Within 6 years of its introduction, onabotulinumtoxinA accounted for almost half of third-line treatments initiated. Conclusion: Overall, third-line therapies for non-neurogenic overactive bladder are utilized infrequently among privately insured women. Over the past decade, the introduction of new treatment options has led to a shift in the type of treatment initiated, rather than to an increase in the overall utilization of third-line therapies.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
StatePublished - May 2023

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019'. Together they form a unique fingerprint.

Cite this